<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03839082</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00153750</org_study_id>
    <nct_id>NCT03839082</nct_id>
  </id_info>
  <brief_title>Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>A Randomized Controlled Pilot Trial of a Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Association for the Study of Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at physical activity and nutrition in patients with non-alcoholic fatty
      liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). The researchers will see if
      providing patients with NAFLD/NASH with specific physical activity and nutrition feedback as
      an addition to their usual clinical care helps them to lose weight and improve liver-related
      parameters.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Enrollment and interactions/interventions are temporarily paused due to COVID-19 and are
    expected to resume. This is not a suspension of IRB approval.
  </why_stopped>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hepatic steatosis as measured controlled attenuation parameter (CAP) score</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>CAP score is generated by a fibroscan. Scores are reported in dB/M ranging from 100-400, with lower scores indicating less hepatic steatosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in body weight</measure>
    <time_frame>Baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity as measured by International Physical Activity Questionnaire (IPAQ)</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>The IPAQ is a validated questionnaire that obtains information on days and minutes per week of different types of physical activity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Usual Care then FitBit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the waitlist control arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FitBit then Usual Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention includes education, physical activity, and a nutrition assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care then FitBit</intervention_name>
    <description>Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).</description>
    <arm_group_label>FitBit then Usual Care</arm_group_label>
    <arm_group_label>Usual Care then FitBit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FitBit then Usual Care</intervention_name>
    <description>Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.</description>
    <arm_group_label>FitBit then Usual Care</arm_group_label>
    <arm_group_label>Usual Care then FitBit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic
             steatohepatitis (NASH)

          -  Access to mobile phone/tablet/ or computer compatible with FitBit application and
             ability to use said device and application

          -  Ability to participate in physical activity

        Exclusion Criteria:

          -  Any other form of liver disease( Alcohol related liver disease; viral hepatitis,
             autoimmune liver disease, hereditary forms of liver disease, etc.)

          -  History of decompensated cirrhosis

          -  Plans for invasive procedures or other regimented lifestyle programs for weight
             reduction

          -  Cardiovascular event in the previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Konerman</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Monica Tincopa</investigator_full_name>
    <investigator_title>Clinical Lecturer in Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Mobile Technology</keyword>
  <keyword>Weight</keyword>
  <keyword>Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

